Navigation Links
Waters Introduces Ostro Sample Preparation Products
Date:9/14/2010

MILFORD, Mass., Sept. 14 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today introduced the new Ostro™ Sample Preparation Plate, representing a novel approach for the removal of phospholipids from biological samples. When compared to other phospholipid removal devices and traditional liquid-liquid extraction (LLE) methods, Ostro removes up to 30 times more phospholipids.

Phospholipids have been cited as a major cause of matrix effects in the LC/MS analysis of biological samples. Ostro, with its proprietary, patent-pending design, was specifically created to overcome this hurdle by offering a "best-in-class" solution that removes multiple families of phospholipids.

The Ostro 96-well plate format utilizes in-well protein precipitation with a single, rapid, pass-through method that provides a quick, reliable, and reproducible solution.

"We are excited and proud to introduce Ostro as an extension of our comprehensive family of 96-well sample preparation plates," comments Dr. Diane Diehl, Director, Sample Preparation, Waters Division. "Ostro will be a valuable tool for researchers who are struggling with phospholipid interferences, and provide a complimentary solution to Oasis® SPE products -- Waters premier solid-phase extraction solution."

For more information on Waters® Ostro Sample Preparation Products:

Brochure:

http://www.waters.com/webassets/cms/library/docs/720003695en.pdf

Product information:

http://www.waters.com/waters/nav.htm?cid=10156075

About Waters Chemistry Products

Waters provides the industry's broadest and deepest product offering manufactured to industry benchmark quality requirements by a world-class manufacturing organization and supported by highly-skilled and trained support teams. Waters maintains one of the largest applications databases of its kind surpassing 60,000 individual citations, abstracts, applications notes and scientific articles.

About Waters Corporation (www.waters.com)

For more than 50 years, Waters Corporation creates business advantages for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality worldwide.

Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.

With revenue of $1.5 billion in 2009 and 5,200 employees, Waters is driving scientific discovery and operational excellence for customers worldwide.

Waters, the Science of What's Possible, Oasis and Ostro are trademarks of Waters Corporation.


'/>"/>
SOURCE Waters Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard
2. New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals
3. Waters Corporation and NIBRT Partner to Bring Greater Control and Predictability to Biopharmaceutical Processing
4. Waters Expands Xevo MS Instrument Platform With Next-Generation Mass Spectrometers
5. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
6. Dr. Dello Russo Introduces the New EYE-Q Lasik
7. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
8. Wedgewood Introduces Refresh(TM) Exchange-Program: Free Exchange of Expired Veterinary Compounded Medications Solves Key Industry Problem
9. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
10. Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology
11. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
Breaking Medicine News(10 mins):